en · de · es · fr · pt
tirzepatide-notes.peptides3626.com › Blog › Tirzepatide Pharmacology And Development History — Complete Guide

Tirzepatide Pharmacology And Development History — Complete Guide

By Editorial Desk · published 2026-05-03 · last reviewed 2026-06-03 · Blog

方法验证 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-06-03. Numbers and descriptions here follow the published literature rather than marketing material.

Tirzepatide Pharmacology and Development History

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Tirzepatide 分子背景与靶点

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强,从而延长循环半衰期,支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征,减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用,属于既定的药代动力学策略。

该化合物的名称与结构由国际非专利名称体系统一维持,不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。

Tirzepatide at a glance

PropertyValueNotes
Molecular classModified synthetic peptide39-residue backbone with non-natural residues
Receptor targetsGIP and GLP-1Dual incretin receptor agonist
Approximate molecular mass4,813 DaCalculated from the peptide sequence
Administration routeSubcutaneous injectionWeekly schedule in approved products
Albumin bindingPresentMediated by a C20 fatty diacid side chain

Molecular Basis and Receptor Pharmacology

At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.

An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.

Related pages on this site

Background And Receptor Mechanism

Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.

Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.

Handling, Storage, and Analytical Methods

Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.

Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.

储存处理与检测方法

质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持,单次测定不足以判定批次的稳定性。实验室之间方法转移时,色谱柱品牌与梯度差异常导致保留时间漂移,因此方法验证十分必要。

固体状态的 tirzepatide 通常以冻干粉形式保存,推荐在低温、避光、干燥条件下存放,常见区间为 2 至 8 摄氏度,长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出,从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。

Reference notes

MALDI can also detect carbapenemase of carbapenem-resistant enterobacteriaceae, including Acinetobacter baumannii and Klebsiella pneumoniae. However, most proteins that mediate antibiotic resistance are larger than MALDI-TOF's 2000–20,000 Da range for protein peak interpretation and only occasionally, as in the 2011 Klebsiella pneumoniae carbapenemase (KPC) outbreak at the NIH, a correlation between a peak and resistance conferring protein can be made.

==== Surgery ==== Tranexamic acid is sometimes used in orthopedic surgery to reduce blood loss, to the extent of reducing or altogether abolishing the need for perioperative blood transfusion. It is of proven value in clearing the field of surgery and reducing blood loss when given before or after surgery. Drain and number of transfusions are reduced. In surgical corrections of craniosynostosis in children it reduces the need for blood transfusions. In spinal surgery (e.g., scoliosis), correction with posterior spinal fusion using instrumentation, to prevent excessive blood loss. In cardiac surgery, both with and without cardiopulmonary bypass (e.g., coronary artery bypass surgery), it is used to prevent excessive blood loss.

The series' first program War, Oil and Power was compiled and released in 1990, before the war broke out. News World Order was the title of another program in the series; it focused on the media's complicity in promoting the war, as well as Americans' reactions to the media coverage. Media watchdog group Fairness and Accuracy in Reporting (FAIR) critically analyzed media coverage during the war in various articles and books, such as the 1991 Gulf War Coverage: The Worst Censorship was at Home.

Although it is not entirely clear which gene causes the resistance phenotype, there is strong evidence supporting the correlation between a mutation in the membrane transporter ABCC2 and Bt resistance. Other studies with greenhouse-evolved population of Bt resistant cabbage looper demonstrate that the downregulation of the aminopeptidase N, APN1, results in its resistance.

==== Harris campaign ==== Harris framed her campaign as "a choice between freedom and chaos" and based it around the ideals of "freedom" and "the future". The Harris campaign sought to highlight her experience as an attorney general and a prosecutor to "prosecute the case" against Trump by pointing out his 34 felony convictions and the impacts of the overturning of Roe v. Wade. Harris had taken liberal positions on a number of issues in her bid for the 2020 Democratic nomination; in 2024, she shifted several of those positions toward the political center and embraced many of Biden's domestic policy stances. Harris focused her economic proposals on the cost of groceries, housing and healthcare.

Sources: en.wikipedia.org

Reference notes

=== EC 1.5.1 With NAD+ or NADP+ as acceptor === EC 1.5.1.1: 1-piperideine-2-carboxylate/1-pyrroline-2-carboxylate reductase (NAD(P)H) EC 1.5.1.2: pyrroline-5-carboxylate reductase EC 1.5.1.3: dihydrofolate reductase EC 1.5.1.4: Now included with EC 1.5.1.3 dihydrofolate reductase EC 1.5.1.5: methylenetetrahydrofolate dehydrogenase (NADP+) EC 1.5.1.6: formyltetrahydrofolate dehydrogenase EC 1.5.1.7: saccharopine dehydrogenase (NAD+, L-lysine-forming) EC 1.5.1.8: saccharopine dehydrogenase (NADP+, L-lysine-forming) EC 1.5.1.9: saccharopine dehydrogenase (NAD+, L-glutamate-forming) EC 1.5.1.10: saccharopine dehydrogenase (NADP+, L-glutamate-forming) EC 1.5.1.11: D-octopine dehydrogenase EC 1.5.1.12: Now EC 1.2.1.88, L-glutamate γ-semialdehyde dehydrogenase EC 1.5.1.13: Now EC 1.17.1.5, nicotinate dehydrogenase EC 1.5.1.14: Now included with EC 1.5.1.21 Δ1-piperideine-2-carboxylate reductase EC 1.5.1.15: methylenetetrahydrofolate dehydrogenase (NAD+) EC 1.5.1.16: D-lysopine dehydrogenase EC 1.5.1.17: alanopine dehydrogenase EC 1.5.1.18: ephedrine dehydrogenase EC 1.5.1.19: D-nopaline dehydrogenase EC 1.5.1.20: methylenetetrahydrofolate reductase (NAD(P)H) EC 1.5.1.21: 1-piperideine-2-carboxylate/1-pyrroline-2-carboxylate reductase (NADPH) EC 1.5.1.22: strombine dehydrogenase EC 1.5.1.23: tauropine dehydrogenase EC 1.5.1.24: N5-(carboxyethyl)ornithine synthase EC 1.5.1.25: thiomorpholine-carboxylate dehydrogenase EC 1.5.1.26: β-alanopine dehydrogenase EC 1.5.1.27: 1,2-dehydroreticulinium reductase (NADPH) EC 1.5.1.28: opine dehydrogenase EC 1.5.1.29: Now covered by EC 1.5.1.38 [FMN reductase (NADPH)], EC 1.5.1.39 [FMN reductase [NAD(P)H])] and EC 1.5.1.41 (riboflavin reductase [NAD(P)H]) EC 1.5.1.30: flavin reductase (NADPH) EC 1.5.1.31: berberine reductase EC 1.5.1.32: vomilenine reductase EC 1.5.1.33: pteridine reductase EC 1.5.1.34: 6,7-dihydropteridine reductase EC 1.5.1.35: identical to EC 1.2.1.19, aminobutyraldehyde dehydrogenase, as the substrates 1-pyrroline and 4-aminobutanal are interconvertible EC 1.5.1.36: flavin reductase (NADH) EC 1.5.1.37: FAD reductase (NADH) EC 1.5.1.38: FMN reductase (NADPH) EC 1.5.1.39: FMN reductase (NAD(P)H) EC 1.5.1.40: 8-hydroxy-5-deazaflavin:NADPH oxidoreductase EC 1.5.1.41: riboflavin reductase (NAD(P)H) EC 1.5.1.42: FMN reductase (NADH) EC 1.5.1.43: carboxynorspermidine synthase EC 1.5.1.44: festuclavine dehydrogenase EC 1.5.1.45: FAD reductase (NAD(P)H) EC 1.5.1.46: agroclavine dehydrogenase EC 1.5.1.47: dihydromethanopterin reductase [NAD(P)+] EC 1.5.1.48: 2-methyl-1-pyrroline reductase EC 1.5.1.49: 1-pyrroline-2-carboxylate reductase [NAD(P)H] EC 1.5.1.50: dihydromonapterin reductase EC 1.5.1.51: N-[(2S)-2-amino-2-carboxyethyl]-L-lutamate dehydrogenase EC 1.5.1.52: staphylopine dehydrogenase EC 1.5.1.53: methylenetetrahydrofolate reductase (NADPH) EC 1.5.1.54: methylenetetrahydrofolate reductase (NADH)

In dental anatomy, the apical foramen, literally translated "small opening of the apex," is the tooth's natural opening, found at the root's very tip—that is, the root apex — whereby an artery, vein, and nerve enter the tooth and commingle with the tooth's internal soft tissue, called pulp. Additionally, the apical foramen is the point where the pulp meets the periodontal tissues, the connective tissues that surround and support the tooth. The foramen is located 0.5mm to 1.5mm from the apex of the tooth. Each tooth has an apical foramen.

== Epidemiology == The exact number of cases of rhabdomyolysis is difficult to establish because different definitions have been used. In 1995, hospitals in the U.S. reported 26,000 cases of rhabdomyolysis. Up to 85% of people with major traumatic injuries will experience some degree of rhabdomyolysis. Of those with rhabdomyolysis, 10–50% develop acute kidney injury. The risk is higher in people with a history of illicit drug use, alcohol misuse, or trauma when compared to muscle diseases, and it is particularly high if multiple contributing factors occur together. Rhabdomyolysis accounts for 7–10% of all cases of acute kidney injury in the U.S. Crush injuries are common in major disasters, especially in earthquakes. The aftermath of the 1988 Spitak earthquake prompted the establishment, in 1995, of the Renal Disaster Relief Task Force, a working group of the International Society of Nephrology (a worldwide body of kidney experts). Its volunteer doctors and nurses assisted for the first time in the 1999 İzmit earthquake in Turkey, where 17,480 people died, 5392 were hospitalized, and 477 received dialysis, with positive results. Treatment units are generally established outside the immediate disaster area, as aftershocks could potentially injure or kill staff and make equipment unusable. Acute exertional rhabdomyolysis happens in 2% to 40% of people going through basic training for the United States military. In 2012, the United States military reported 402 cases. Another group at increased risk is firefighters.

==== C4 ==== C4 plants capture carbon dioxide in their mesophyll cells (using an enzyme called phosphoenolpyruvate carboxylase which catalyzes the combination of carbon dioxide with a compound called phosphoenolpyruvate (PEP)), forming oxaloacetate. This oxaloacetate is then converted to malate and is transported into the bundle sheath cells (site of carbon dioxide fixation by RuBisCO) where oxygen concentration is low to avoid photorespiration. Here, carbon dioxide is removed from the malate and combined with RuBP by RuBisCO in the usual way, and the Calvin cycle proceeds as normal. The CO2 concentrations in the Bundle Sheath are approximately 10–20 fold higher than the concentration in the mesophyll cells. This ability to avoid photorespiration makes these plants more hardy than other plants in dry and hot environments, wherein stomata are closed and internal carbon dioxide levels are low. Under these conditions, photorespiration does occur in C4 plants, but at a much lower level compared with C3 plants in the same conditions. C4 plants include sugar cane, corn (maize), and sorghum.

Sources: en.wikipedia.org

Notes from published material

Studies show that the EPOC effect exists after both aerobic exercise and anaerobic exercise. In a 1992 Purdue study, results showed that high intensity, anaerobic type exercise resulted in a significantly greater magnitude of EPOC than aerobic exercise of equal work output. For exercise regimens of comparable duration and intensity, aerobic exercise burns more calories during the exercise itself, but the difference is partly offset by the higher increase in caloric expenditure that occurs during the EPOC phase after anaerobic exercise. Anaerobic exercise in the form of high-intensity interval training was also found in one study to result in greater loss of subcutaneous fat, even though the subjects expended fewer than half as many calories during exercise. Whether this result was caused by the EPOC effect has not been established, and the caloric content of the participants' diet was not controlled during this particular study period. Most researchers use a measure of EPOC as a natural part of the quantification or measurement of exercise and recovery energy expenditure; to others this is not deemed necessary. After a single bout or set of weight lifting, Scott et al. found considerable contributions of EPOC to total energy expenditure. In their 2004 survey of the relevant literature, Meirelles and Gomes found: "In summary, EPOC resulting from a single resistance exercise session (i.e., many lifts) does not represent a great impact on energy balance; however, its cumulative effect may be relevant".

The two substrates of this enzyme are sulcatol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are sulcatone, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is sulcatol:NAD+ oxidoreductase.

==== Oily skin ==== Oily skin is caused by over-active sebaceous glands, that produce a substance called sebum, a naturally healthy skin lubricant. A high glycemic-index diet and dairy products (except for cheese) consumption increase IGF-1 generation, which in turn increases sebum production. Overwashing the skin does not cause sebum overproduction but may cause dryness. When the skin produces excessive sebum, it becomes heavy and thick in texture, known as oily skin. Oily skin is typified by shininess, blemishes and pimples. The oily-skin type is not necessarily bad, since such skin is less prone to wrinkling, or other signs of ageing, because the oil helps to keep needed moisture locked into the epidermis (outermost layer of skin). The negative aspect of the oily-skin type is that oily complexions are especially susceptible to clogged pores, blackheads, and buildup of dead skin cells on the surface of the skin. Oily skin can be sallow and rough in texture and tends to have large, clearly visible pores everywhere, except around the eyes and neck.

Risk factors for complications and death include age, hemodynamic parameters (such as heart failure, cardiac arrest on admission, systolic blood pressure, or Killip class of two or greater), ST-segment deviation, diabetes, serum creatinine, peripheral vascular disease, and elevation of cardiac markers.

== 1942: Battle of Stalingrad == On 1 January 1942, the 4th Panzer Group was redesignated 4th Panzer Army. The 4th Panzer Army held defensive positions in the spring of 1942 and then was reinforced, re-fit and transferred to Army Group South for Case Blue, its offensive in Southern Russia. Command was transferred to general Hermann Hoth in June. As the operation progressed, Hitler divided Army Group South into two army groups. Army Group A which was composed of the German 17th Army and 1st Panzer Army and Army Group B which was composed of 6th Army and the 4th Panzer Army. The 4th Panzer Army was on 1 Aug 1942 composed of:

Sources: en.wikipedia.org

Frequently asked questions

What receptors does tirzepatide target?

It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.

How does albumin binding affect tirzepatide?

A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.

When was tirzepatide first approved?

The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.

Tirzepatide 属于哪一类分子?

它属于合成修饰肽,同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂,与选择性 GLP-1 激动剂在靶点范围上不同。

Network